MedTrace Logo

IOP Reduction in Pigmentary Glaucoma Using DSLT

NCT07281391 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 45

Last updated 2026-04-09

No results posted yet for this study

Summary

This study is a single-site, single-arm, prospective, observational study of IOP reduction after DSLT. Subjects will be assessed up to 12 months post-operatively. Clinical evaluations will include IOP and number of glaucoma medications.

Conditions

  • Pigmentary Dispersion Syndrome
  • Pigmentary Dispersion Glaucoma

Interventions

DEVICE

Voyager DSLT

DSLT is an innovative adaptation of traditional SLT. Rather than using a gonioscopic lens, DSLT applies laser energy directly through the limbus to the trabecular meshwork in a few seconds.

Sponsors & Collaborators

  • Sengi

    collaborator INDUSTRY

  • Mann Eye Institute

    lead OTHER

Principal Investigators

  • Alex Hacopian, MD · Mann Eye Institute

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-19
Primary Completion
2027-04-01
Completion
2027-04-01
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07281391 on ClinicalTrials.gov